



Neuren Establishes Strategic Alliance with the University of Cambridge

29 June 2007: Neuren Pharmaceuticals (ASX: NEU) today announced that it has formed a strategic alliance with the University of Cambridge, United Kingdom, to conduct research on the molecular mechanisms of its compounds.

Professor Stewart Gilmour, formerly a consultant to Neuren, has moved to Cambridge and will manage the collaboration. The research will be undertaken by Professor Gilmour and Professor Andrew Wylie FRS who is recognised for his research on mechanisms of cell death particularly in brain cells from the Mammalian Molecular Genetics Group in the Department of Pathology of the University.

The alliance will further Neuren's understanding of the mechanisms involved in the protection of brain cells by its drugs, particularly the pre-clinical candidates, and may provide important leads to other indications for these compounds. Apoptosis or cell death is a key feature of both acute and chronic neurodegenerative disease and a critical target for drug development across a wide range of diseases and conditions.

The Department has taken leadership in developing state of the art molecular and cellular analytical systems (in particular, array-based biological systems) to which Neuren will have unlimited access, at no cost. Neuren will also be free to interact with a diverse spectrum of research scientists within the various departmental groups at Cambridge.

Mr David Clarke, Chief Executive Officer of Neuren commented that, "As we progress our pipeline an opportunity to have a greater understanding of the mode of action of these compounds at a detailed molecular level is an advantage. Our in-house development program will be greatly enhanced by access to the intellectual expertise and cutting-edge technologies in this centre of advanced research."

About Neuren Pharmaceuticals

Neuren Pharmaceuticals (ASX: NEU) is a biopharmaceutical company developing novel therapeutics in the fields of brain injury and diseases and metabolic disorders. The Neuren portfolio consists of six product families, targeting markets with large unmet needs and limited competition. Neuren has three lead candidates, Glypromate[®] and NNZ-2566, presently in clinical trials to treat a range of acute neurological conditions, and NNZ-2591 in preclinical development for Parkinson's and other chronic conditions. Neuren has commercial and development partnerships, including with the U.S. Army Walter Reed Army Institute of Research, Metabolic Pharmaceuticals, UCLA Medical Center and the National Trauma Research Institute in Melbourne.

For more information, please visit Neuren's website at www.neurenpharma.com

Contact details:

Neuren	Media and investor relations
David Clarke CEO T: 1 800 259 181 (Australia) T: +64 9 529 3942 (NZ) M: +64 21 988 052	Rebecca Piercy Buchan Consulting T: +61 2 9237 2800 M: +61 422 916 422